A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

NCT04926324 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Sponsor terminated

Conditions

Rectal Neoplasms
Rectal Neoplasm Malignant

Interventions

DRUG: Niraparib
DRUG: Dostarlimab
RADIATION: Short course radiation

Sponsor

University of Iowa

Collaborators

[object Object]